Life sciences venture capital funds Burrill & Company and the Malaysian Life Sciences Capital Fund (MLSCF) have invested in Gevo, Inc., a company focused on the development of biofuels technology based on butanol and its derivatives.
The investment comes less than one year after Virgin Green Fund joined founding investor Khosla Ventures in a Series B round. The amount of the investment was not disclosed.
As an advanced biofuel, butanol has an energy content similar to gasoline and it is compatible with the current energy transportation system, including pipelines. Gevo’s advanced biofuels technology also enables the production of fuels for the diesel and jet markets as well as the production of green chemicals derived from renewable resources.
"Gevo is an exciting company. We welcome Burrill & Company and MLSCF as investors," said Vinod Khosla, founder of Khosla Ventures. "I am pleased that Ganesh Kishore, with all of his biotech experience and Mark Noetzel with all of his British Petroleum experience, have joined Gevo’s board of directors."
Formed in 2005, Gevo is dedicated to bringing renewable cost-effective alternatives for fossil fuels and chemicals to consumers worldwide. "Our goal is to meet increasing energy demands while reducing our impact on the earth," said Gruber. "We will accomplish this by converting renewable resources into fuels and green chemicals." For more information about Gevo, Inc.
About Burrill and Company:
Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, industrial (biomaterials/bioprocess) and agricultural biotechnology, pharmaceuticals, health & wellness and human healthcare related medical technologies, with over $950 million under management. Burrill’s technical and venture investing competence spans the entire spectrum of life sciences. In addition, Burrill is a leader in life science strategic partnering, an invaluable practice to build value in portfolio companies and to accelerate their growth and development. Burrill is also the sponsor and facilitator of a number of leading annual industry conferences and publishes the seminal annual report on the state of the biotechnology industry. For more information, visit www.burrillandco.com.
About Malaysian Life Sciences Capital Fund (MLSCF):
Formed in late 2006, MLSCF is a life sciences venture fund specializing in investments in the areas of agriculture, industrial and healthcare biotechnology both within and outside of Malaysia. MLSCF expects to leverage global resources to facilitate the growth of Malaysia’s life sciences industry and in the case of industrial biotechnology, is particularly interested in technologies that can utilize biomass, a major resource of Malaysia. The Fund is co-managed by Malaysian Technology Development Corporation Sdn Bhd (MTDC) and Burrill & Company. For more information, visit www.mlscf.com.
Loading...